In the Claims

B1

26. (twice Amended) A dosage formulation comprising an effective amount of human or humanized monoclonal antibodies suitable for intravenous administration to humans, the antibodies consisting of antibodies neutralizing Shiga like toxin II *in vivo*, to prevent or treat hemolytic uremic syndrome in a human.

B2

31. (Amended) The dosage formulation of claim 26 wherein the antibodies are effective to prevent neurological signs of hemolytic uremic syndrome or lesions, wherein the neurological signs or lesions are selected from the group consisting of cerebral hemorrhaging, paddling, head-pressing, ataxia, convulsions and wasting.

B3

35. (Amended) The dosage formulation of claim 26 producing a serum level of anti-Shiga toxin II antibodies of at least [about] 0.5 micrograms/ml.